Ferric carboxymaltose

For adult patients with iron deficiency anemia of various etiologies.

Trade name Injectafer.

Indicated for the treatment of iron deficiency in patients with intolerance to oral iron or have had an unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.

750 mg can be delivered in a single dose and two doses can be given separately at seven-day intervals for a total cumulative dose of 1500 mg.

Is administered intravenously over 15 minutes, or by slow push injection at 2 mL per minute for at least 7.5 minutes.

Among patients with heart failure and reduced ejection fraction and iron deficiency carboxy ferric carboxymaltose therapy reduces symptoms and improves quality of life: there is, however, no difference between ferric carboxymaltose and placebo with respect to composite of death, hospitalizations for heart failure, or six minute walk distance (MentzR).

Can cause high rates of hypophosphatemia by increasing circulation concentration of biologically active fibroblast growth factor 23, which causes hypophosphatemia by stimulating urinary phosphate excretion and reducing serum 1, 25-dihydroxyvitamin D levels.

Hypophosphatemia can cause rhabdomyolysis, heart failure, and respiratory failure, and chronic hypophosphatemia can be complicated by osteomalacia and fractures.

Serious hypersensitivity reactions, including anaphylactic type reactions have been reported.

Serious anaphylactic reactions have been reported in 0.1% of subjects.

Hypertension is reported in 3.8% of patients.

More than 7% of patients report nausea, 3.6% experience flushing and 2% experience dizziness.

Treatment should not exceed 1500 mg of iron per course.

Leave a Reply

Your email address will not be published. Required fields are marked *